{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:15:16Z","timestamp":1793499316132,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of HR17031, a fixed\u2010ratio combination of basal insulin analogue (INS068) and GLP\u20101 receptor agonist (noiiglutide), versus its components alone in patients with type 2 diabetes uncontrolled on metformin with or without a second oral antidiabetic drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      This phase 2 multicentre trial randomised 455 patients with type 2 diabetes (HbA1c 7.5%\u201311.0% [58.0\u201397.0\u2009mmol\/mol]; previous metformin \u00b1 another oral antidiabetic drug) 2:2:1 to HR17031 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009183), INS068 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009182) or noiiglutide (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200990). The primary endpoint was HbA1c change from baseline to week 26.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HR17031 achieved a greater reduction in HbA1c than INS068 and noiiglutide (\u22122.4% [\u221226\u2009mmol\/mol] vs. \u22121.5% [\u221216\u2009mmol\/mol] and \u22121.7% [\u221219\u2009mmol\/mol]), indicating superiority for HR17031 over both INS068 and noiiglutide (least\u2010squares mean difference\u2009=\u2009\u22120.9% [\u221210\u2009mmol\/mol] and \u22120.7% [\u22127\u2009mmol\/mol], respectively; both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). More patients reached HbA1c target &lt;7.0% (53\u2009mmol\/mol) and \u22646.5% (48\u2009mmol\/mol) with HR17031 (&lt;7.0%, 81.4%; \u22646.5%, 74.3%) than INS068 (47.8%; 26.4%) and noiiglutide (55.6%; 41.1%). HR17031 resulted in no weight gain in contrast to INS068 (\u22120.1 vs. 2.0\u2009kg;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Incidence of level 2\/3 hypoglycaemia was similar with HR17031 (5.5%) and INS068 (4.4%), and lower with noiiglutide (1.1%). HR17031 demonstrated fewer instances of nausea (7.2%), diarrhoea (7.2%), and vomiting (2.8%) than noiiglutide (15.6%, 21.1%, and 20.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HR17031 is effective and well\u2010tolerated in patients with type 2 diabetes uncontrolled on metformin with or without a second oral antidiabetic drug.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70036","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:48:47Z","timestamp":1756288127000},"page":"6428-6439","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety benefits of\n                    <scp>HR17031<\/scp>\n                    , a fixed\u2010ratio combination of\n                    <scp>INS068<\/scp>\n                    and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open\u2010label, randomised, parallel three\u2010arm, treat\u2010to\u2010target trial"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-1598","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism People's Hospital of Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debing","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The Third Hospital of Changsha  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Lin","sequence":"additional","affiliation":[{"name":"Clinical Research &amp; Development Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Dong","sequence":"additional","affiliation":[{"name":"Clinical Research &amp; Development Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Research &amp; Development Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Yueyang Central Hospital  Yueyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Affiliated Hospital of Weifang Medical University  Weifang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Huai'an First People's Hospital  Huai'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The Central Hospital of Wuhan  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanren","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research &amp; Development Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Ye","sequence":"additional","affiliation":[{"name":"Clinical Research &amp; Development Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1114"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13286"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14722"},{"issue":"4","key":"e_1_2_10_8_1","first-page":"311","article-title":"Guidelines for the prevention and treatment of type 2 diabetes in China (2020 edition)","volume":"37","author":"Chinese Diabetes Society","year":"2021","journal-title":"Chin J Endocrinol Metab"},{"issue":"1","key":"e_1_2_10_9_1","first-page":"S1","article-title":"Standards of medical care in diabetes","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1294810"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15407"},{"key":"e_1_2_10_12_1","first-page":"3449","article-title":"Pharmacokinetic study of noiiglutide injection, INS068 injection and the compound preparation in Chinese healthy subjects","volume":"23","author":"Xing XZJ","year":"2023","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"e_1_2_10_14_1","volume-title":"Technical Guidelines for Clinical Research and Development of Drugs for Adult Type 2 Diabetes (in Chinese). Version 2023","author":"Center for Drug Evaluation, National Medical Products Administration","year":"2025"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.08.003"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12129"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0132-0"},{"key":"e_1_2_10_19_1","first-page":"7","volume-title":"Diabetes: from Research to Clinical Practice","author":"G\u00f6k\u00e7ay Canpolat A","year":"2021"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02344-1"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14232"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.10.003"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0653"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2014.0188"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70036","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:22:35Z","timestamp":1771309355000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/dom.70036"],"URL":"https:\/\/doi.org\/10.1111\/dom.70036","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"2025-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}